Literature DB >> 18972122

[Glucocorticoids in rheumatology].

R Dziurla1, F Buttgereit.   

Abstract

Glucocorticoids (GC) are effective drugs which are often used in rheumatology. However, they have a considerable potential for frequent and sometimes serious side effects that restrict their use. Their mechanisms of action are either receptor dependent (specific) or independent (unspecific) on the genomic as well as the non-genomic level. Many adverse effects are predominantly caused by transactivation while the desired effects are mostly mediated by transrepression. Treatment strategies are sub-classified into low, medium, high, very high dose and pulse therapy based on criteria such as dose, indication, duration of treatment and potential risk of adverse events. The musculoskeletal, gastrointestinal, neuro-endocrino-immunological, opthalmological and neuropsychiatric systems are examples where adverse effects may occur.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18972122     DOI: 10.1007/s00393-008-0365-7

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  14 in total

1.  Glucocorticoid action and novel mechanisms of steroid resistance: role of glucocorticoid receptor-interacting proteins for glucocorticoid responsiveness.

Authors:  A-C Wikström
Journal:  J Endocrinol       Date:  2003-09       Impact factor: 4.286

Review 2.  Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action.

Authors:  Frank Buttgereit; Rainer H Straub; Martin Wehling; Gerd-Rüdiger Burmester
Journal:  Arthritis Rheum       Date:  2004-11

Review 3.  Developments in glucocorticoid therapy.

Authors:  Johannes W J Bijlsma; Kenneth G Saag; Frank Buttgereit; José A P da Silva
Journal:  Rheum Dis Clin North Am       Date:  2005-02       Impact factor: 2.670

4.  Bone loss and turnover after cardiac transplantation.

Authors:  E Shane; M Rivas; D J McMahon; R B Staron; S J Silverberg; M J Seibel; D Mancini; R E Michler; K Aaronson; V Addesso; S H Lo
Journal:  J Clin Endocrinol Metab       Date:  1997-05       Impact factor: 5.958

Review 5.  The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis.

Authors:  F Buttgereit; K G Saag; M Cutolo; J A P da Silva; J W J Bijlsma
Journal:  Scand J Rheumatol       Date:  2005       Impact factor: 3.641

Review 6.  Use of systemic glucocorticosteroids in pregnancy: be alert but not alarmed.

Authors:  Gordon J Rennick
Journal:  Australas J Dermatol       Date:  2006-02       Impact factor: 2.875

7.  Membrane glucocorticoid receptors are down regulated by glucocorticoids in patients with systemic lupus erythematosus and use a caveolin-1-independent expression pathway.

Authors:  C M Spies; D H S Schaumann; T Berki; K Mayer; M Jakstadt; D Huscher; C Wunder; G-R Burmester; A Radbruch; R Lauster; A Scheffold; F Buttgereit
Journal:  Ann Rheum Dis       Date:  2006-01-31       Impact factor: 19.103

8.  Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial.

Authors:  Frank Buttgereit; Gisela Doering; Achim Schaeffler; Stephan Witte; Stanislaw Sierakowski; Erika Gromnica-Ihle; Slawomir Jeka; Klaus Krueger; Jacek Szechinski; Rieke Alten
Journal:  Lancet       Date:  2008-01-19       Impact factor: 79.321

Review 9.  Optimum management of glucocorticoid-treated patients.

Authors:  Subbulaxmi Trikudanathan; Graham T McMahon
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2008-03-18

10.  Membrane glucocorticoid receptors (mGCR) are expressed in normal human peripheral blood mononuclear cells and up-regulated after in vitro stimulation and in patients with rheumatoid arthritis.

Authors:  Burkhard Bartholome; Cornelia M Spies; Timo Gaber; Sebastian Schuchmann; Timea Berki; Désirée Kunkel; Maren Bienert; Andreas Radbruch; Gerd-Rüdiger Burmester; Roland Lauster; Alexander Scheffold; Frank Buttgereit
Journal:  FASEB J       Date:  2004-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.